The collaboration represents a synergistic blend of Jiva.ai's cutting-edge AI capabilities  and Aevice Health's expertise in developing a proprietary remote patient monitoring platform  that empowers individuals to proactively manage their respiratory health. The project will see  the development of an AI capable of asthma exacerbation prediction, utilizing Aevice Health’s  FDA-cleared AeviceMD, to provide asthma patients with a groundbreaking tool to take charge  of their conditions. 

Asthma poses a significant global healthcare burden, with billions spent on reactive  management only in the advanced stages. Advancements in remote technology has  generated extensive data that holds promise for early asthma prediction and management.  Similarly, development in AI technology now offers a possibility to creating diagnostic and  prognostic tools that could reduce patient suffering, save lives, and cut costs to heathcare  systems. 

Implementing a “multimodal AI”, the ability to read multiple different types of data to  make predictions, within a clinical setting can be complex. Multimodal AI ideally involves  adding new predictors to existing AI models, which is desirable but technologically and  logistically difficult in healthcare. With the FDA-cleared AeviceMD, biomarkers of interest for  asthma exacerbations can be collected unobtrusively and continuously within and outside of  clinical settings. The diverse data collected can then be integrated into the multimodal AI to  create an early warning system for asthmatic patients to get the care they need before their  asthma escalates. 

"Combining Jiva.ai's no-code AI platform with Aevice Health’s advanced remote  patient monitoring platform is a significant leap forward in the realm of healthcare innovation,”  said Dr Manish Patel, CEO at Jiva.ai. “We are excited about the potential impact of this  collaboration, as it underscores our commitment to leveraging technology to enhance patient  outcomes and improve overall healthcare delivery.” 

Aevice Health's CTO, Dr Rex Tan, echoed this sentiment, stating, "Asthma is a global  health concern, and our collaboration with Jiva.ai through the Enterprise Singapore and  Innovate UK jointly funded co-innovation project aligns with our mission to empower  individuals to actively manage their respiratory health.”This project will leverage the strengths of both companies to develop an intelligent and  user-friendly care regime that integrates seamlessly into patients' lives. The collaboration is  set to redefine the landscape of respiratory health management, demonstrating the potential  of AI-driven solutions in addressing complex healthcare challenges. 

The UK-Singapore Collaborative R&D grant call is a programme jointly launched by  Innovate UK, part of the UK Research and Innovation, and Enterprise Singapore. The grant’s  objective is to fund business-led collaborative research and development (CR&D) projects  between the UK and Singapore, focused on industrial research in particular sectors including  health and life sciences.  

As the project unfolds, Jiva.ai and Aevice Health anticipate not only advancing the  frontiers of medical technology but also making substantial contributions to the broader  discourse on harnessing AI for proactive healthcare measures.